PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022
May 26, 2022 17:02 ET
|
PDS Biotechnology Corporation
Preliminary data from first 19 patients treated with PDS0101 in combination with KEYTRUDA® (pembrolizumab) demonstrates 41% response rate thus far for first line recurrent or metastatic head and neck...
PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022
May 26, 2022 17:01 ET
|
PDS Biotechnology Corporation
77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months 75% of CPI naïve patients alive at median follow up of 17 months Anti-tumor objective responses seen in...
PDS Biotechnology to Host Conference Call Following Poster Presentations of PDS0101 Data at 2022 ASCO Annual Meeting
May 25, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer...
PDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development
May 18, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer...
PDS Biotech to Participate at Upcoming Investor Conferences
May 17, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer...
PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results
May 11, 2022 07:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer...
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results
April 28, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing molecularly targeted cancer therapies and...
PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
April 27, 2022 10:01 ET
|
PDS Biotechnology Corporation
Preliminary efficacy and safety update on PDS0101 in combination with KEYTRUDA® (pembrolizumab) in first-line recurrent or metastatic HPV-positive head and neck cancerPreliminary efficacy and safety...
PDS Biotech Chief Medical Officer, Lauren V. Wood, to Chair Session at the World Vaccine Congress
April 20, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted...
PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 08, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted...